2022 IDWeek, October 19-23, Washington DC
OMNIvance®
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase Inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects (Poster 216)
David C. Griffith, Jason A. Roberts, Steven C. Wallis, Maria Patricia Hernandez-Mitre, Elizabeth E. Morgan, Shawnee Gehrke, Michael N. Dudley, and Jeffery S. Loutit
Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered in Combination with Meropenem (Poster 615)
Ziad Tarazi, Niki Roos, Ted Page, and David C. Griffith
Meropenem-Xeruborbactam: In Vitro Potency against Gram-Negative Bacteria in Comparison with Marketed and Investigational Beta-lactam (BL)/Beta-lactamase Inhibitor (BLI) Combinations (Poster 1693)
Olga Lomovskaya, Mariana Castanheira, and Jill Lindley
Xeruborbactam (QPX) Potentiates the Activity of β-Lactam Antibiotics Against a Diverse Group of Highly Drug-Resistant Enterobacterales (Poster 1737)
Anthony Newbrough, Giuseppe Fleres, Binghua Hao, Liang Chen, Ryan K Shields, Cornelius J Clancy, and M. Hong Nguyen
Xeruborbactam (QPX) Potentiates the Activity of Multiple β-lactams Against Highly Resistant Pseudomonas aeruginosa to a Greater Degree than Other Beta-Lactamase Inhibitors (Poster 1736)
Giuseppe Fleres, Anthony Newbrough, Binghua Hao, Liang Chen, Ryan K Shields, Cornelius J Clancy, and M. Hong Nguyen
ORAvance™
A Phase 1 Study of the Single-Dose Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase Inhibitor Xeruborbactam Administered as the Isobutyryloxymethyl Oral Prodrug to Healthy Adult Subjects (Poster 218)
David C. Griffith, Jason A. Roberts, Steven C. Wallis, Maria Patricia Hernandez-Mitre, Elizabeth E. Morgan, Michael N. Dudley, and Jeffery S. Loutit
Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered as the Oral Prodrug in Combination with Ceftibuten (Poster 614)
Ziad Tarazi, Niki Roos, Ted Page, and David C. Griffith
Ceftibuten-Xeruborbactam: In Vitro Potency against Enterobacterales in Comparison with Other Oral Beta-lactams (BL) and Beta-lactamase Inhibitor (BLI) Combinations (Poster 1692)
Olga Lomovskaya, Mariana Castanheira, and Jill Lindley
QPX9003
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects (Poster 217)
David C. Griffith, Yehuda Carmeli, Shawnee Gehrke, Elizabeth E. Morgan, Michael N. Dudley, and Jeffery S. Loutit
Pharmacodynamics (PD) of the Lipopeptide QPX9003 Against Acinetobacter baumannii and P. aeruginosa in the Neutropenic Mouse Thigh Infection Model (Poster 616)
Ziad Tarazi, Niki Roos, Ted Page, Jian Li, J. Wang, Kade D. Roberts and David C. Griffith